Lonza Group AG plans to focus on CDMO segment, despite revenue decrease. Click here to read more on the analysis of LZAGY stock.

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...

The Lonza CEO said the company is not under any pressure to exit the Capsules and Health Ingredients (CHI) business and is expecting strong interest for it. Synaffix adds to the flurry of ADC ...

Morgan Stanley (NYSE:MS) analysts adjusted their stance on Lonza Group (LONN:SW) (OTC: LZAGY), downgrading the stock from Overweight to Equalweight, while increasing the price target to CHF625 from ...

MANCHESTER — Eversource, Unitil, and Lonza have solidified their long-standing collaboration by signing new memorandums of understanding that reinforce their commitment to sustainability and ...

Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end ...

DelveInsight's Biologics Drug Substance Manufacturing Market Insights report provides the current and forecast market ...

Lonza Group has been a dominant player in the contract development and manufacturing space for decades. We think the outlook for Lonza looks bright, especially as drug manufacturing becomes more ...

Narrow-moat Lonza delivered solid performance in its core contract development and manufacturing organization business, but softer results from its capsules and health ingredients division ...

Lonza announced its new vision and One Lonza strategy centered around the Lonza Engine, which brings together the company’s unique core competencies that enable outstanding value creation. As part of ...

Investing.com -- Shares of Lonza Group AG (SIX:LONN) fell more than 3% on Wednesday after the company reported full-year 2024 earnings that showed flat revenue growth and a dip in overall sales ...